Triple-negative Breast Cancer
📧 Sign up to get email alerts when something new happens for Triple-negative Breast Cancer.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2026-04-13Clinical Trial Update: Testing the Addition of an Anti-cancer Drug, ASTX727 (Cedazuridine, Decitabine), to Chemotherapy (Paclitaxel) and Immunotherapy (Pembrolizumab) for Metastatic Triple-Negative Breast Cancer [Phase 1]
A Phase 1 trial is evaluating the addition of ASTX727 (cedazuridine/decitabine) to paclitaxel and pembrolizumab for metastatic or unresectab…
-
CLINICAL_TRIALS research · 2026-04-13Clinical Trial Update: Evolutionary Clinical Trial for Novel Biomarker-Driven Therapies [Phase 2]
A Phase 2 trial update from UNC Lineberger Comprehensive Cancer Center for biomarker-driven therapies in breast cancer, currently recruiting…
-
CLINICAL_TRIALS research · 2026-04-13Clinical Trial Update: Comparison of Chemotherapy and Immunotherapy in Neoadjuvant Therapy for TNBC
Clinical trial update on a study comparing chemotherapy versus immunotherapy as neoadjuvant therapy for triple-negative breast cancer, with …
-
CLINICAL_TRIALS research · 2026-04-09Clinical Trial Update: A Nurse-Led, Coping and Supportive Intervention for Patients With Triple-Negative Breast Cancer [NA]
This research trial outlines a nurse-led coping and supportive intervention for patients with triple-negative breast cancer and is not yet r…
-
CLINICAL_TRIALS trial_result · 2026-04-08Clinical Trial Update: Cisplatin With or Without Veliparib in Treating Patients With Recurrent or Metastatic Triple-Negative and/or BRCA Mutation-Associated Breast Cancer With or Without Brain Metastases [Phase 2]
Phase 2 trial evaluating cisplatin with or without veliparib in patients with recurrent or metastatic triple-negative or BRCA mutation-assoc…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2026-04-08Clinical Trial Update: Dose Determining Study of EXS74539 (REC-4539) in Participants With Select Solid Tumors [Phase 1]
This clinical trial update reports a Phase 1 dose-determining study of EXS74539 (REC-4539) in participants with select solid tumors, current…
-
CLINICAL_TRIALS research · 2026-04-08Clinical Trial Update: Platform Study of ADC Rechallenge in ADC-treated Metastatic Breast Cancer [Phase 2]
Phase 2 platform study evaluating rechallenge with antibody-drug conjugates in ADC-treated metastatic breast cancer; recruitment is ongoing.
-
CLINICAL_TRIALS research · 2026-04-07Clinical Trial Update: A Cancer Vaccine (STEMVAC) in Combination With Chemotherapy for the Treatment of PD-L1 Negative Metastatic Triple-Negative Breast Cancer [Phase 2]
Phase 2 clinical trial evaluating STEMVAC in combination with chemotherapy for PD-L1 negative metastatic triple-negative breast cancer, curr…
-
CLINICAL_TRIALS research · 2026-04-07Clinical Trial Update: Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001) [Phase 1, Phase 2]
Genmab is conducting a Phase 1/2 clinical trial of Rinatabart Sesutecan for multiple advanced solid tumors; recruitment is ongoing.
-
CLINICAL_TRIALS trial_result · 2026-04-07Clinical Trial Update: Neoadjuvant Pembrolizumab and Carboplatin Plus Paclitaxel for Stage I Triple-negative Breast Cancer [Phase 2]
Phase 2 neoadjuvant trial evaluating pembrolizumab with carboplatin and paclitaxel for Stage I triple-negative breast cancer is currently ac…
-
CLINICAL_TRIALS other · 2026-04-07Clinical Trial Update: Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab [Phase 3]
Phase 3 clinical trial evaluating pembrolizumab versus observation in people with triple-negative breast cancer who achieved pathologic comp…
-
CLINICAL_TRIALS research · 2026-04-06Clinical Trial Update: Dual-Target CAR-NK Cells for Advanced Breast Cancer HER2+ TNBC [Phase 1, Phase 2]
A Phase 1/2 trial is evaluating dual-target CAR-NK cell therapy for advanced breast cancer, including HER2-positive and triple-negative subt…
-
CLINICAL_TRIALS research · 2026-04-06Clinical Trial Update: A Study of MOv18 IgE in Patients With Solid Tumours That Express Folate Receptor Alpha [Phase 1]
Phase 1 study of MOv18 IgE in solid tumors expressing folate receptor alpha is currently recruiting, evaluating safety and early signals of …
-
CLINICAL_TRIALS research · 2026-04-06Clinical Trial Update: PAveMenT: Palbociclib and Avelumab in Metastatic AR+ Triple Negative Breast Cancer [Phase 1]
Phase 1 trial PAveMenT is evaluating the combination of palbociclib and avelumab in metastatic AR-positive triple-negative breast cancer and…
-
CLINICAL_TRIALS research · 2026-04-06Clinical Trial Update: Nadunolimab in Combination With Gemcitabine Plus Carboplatin in Patients With Advanced Triple Negative Breast Cancer. [Phase 1, Phase 2]
Cantargia's Nadunolimab is being studied in combination with gemcitabine and carboplatin for advanced triple-negative breast cancer in Phase…
-
CLINICAL_TRIALS other · 2026-04-06Clinical Trial Update: Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Patients With Previously Untreated Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer [Phase 3]
Clinical trial update on a Phase 3 study comparing Sacituzumab Govitecan-hziy to physician's choice in previously untreated locally advanced…
-
CLINICAL_TRIALS research · 2026-04-03Clinical Trial Update: Alpelisib/iNOS Inhibitor/Nab-paclitaxel in Patients With HER2 Negative Metaplastic Breast Cancer (MpBC) [Phase 2]
A Phase 2 trial evaluating a combination of alpelisib, an iNOS inhibitor, and nab-paclitaxel in HER2-negative metaplastic breast cancer, wit…
-
CLINICAL_TRIALS other · 2026-04-03Clinical Trial Update: QLC5513 Alone or in Combination With QL1706 in Previously Treated Advanced or Metastatic TNBC. [Phase 2]
A Phase 2 trial evaluating QLC5513 alone or with QL1706 for previously treated advanced or metastatic triple-negative breast cancer is not y…
-
CLINICAL_TRIALS research · 2026-04-03Clinical Trial Update: A Study to Assess CLBR001+ABBV-461 in Subjects With Locally Advanced or Metastatic Breast Cancer [Phase 1]
This clinical trial update describes a Phase 1 study evaluating the combination CLBR001 and ABBV-461 for locally advanced or metastatic brea…
-
CLINICAL_TRIALS trial_result · 2026-04-02Clinical Trial Update: The Efficacy and Safety of Sintilimab Plus Anlotinib Combined With Chemotherapy as Neoadjuvant Therapy in TNBC [Phase 2]
This report covers a Phase 2 clinical trial evaluating the efficacy and safety of combining sintilimab, anlotinib, and chemotherapy as neoad…
-
CLINICAL_TRIALS research · 2026-04-02Clinical Trial Update: This is a Phase 1 Trial of ZM008, an Anti-LLT1 Antibody, Used as Single Agent Followed by Combination Treatment With Toripalimab in Patients With Advanced Solid Tumors [Phase 1]
Phase 1 clinical trial of ZM008, an anti-LLT1 antibody, given as a single agent and then in combination with toripalimab in patients with ad…
-
CLINICAL_TRIALS research · 2026-04-02Clinical Trial Update: Intratumoral INT230-6 Followed by Neoadjuvant Immuno-chemotherapy in Patients With Early TNBC. INVINCIBLE-4-SAKK [Phase 2]
A Phase 2 trial (INVINCIBLE-4-SAKK) testing intratumoral INT230-6 followed by neoadjuvant immuno-chemotherapy for early triple-negative brea…
-
CLINICAL_TRIALS research · 2026-04-02Clinical Trial Update: A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer [Phase 3]
A Phase III randomized trial evaluating Dato-DXd in combination with Durvalumab for neoadjuvant/adjuvant treatment in triple-negative or hor…
-
CLINICAL_TRIALS trial_result · 2026-04-02Clinical Trial Update: Phase II Trial of Ivonescimab in Combination With Carboplatin + Docetaxel in Patients With Early-Stage Triple Negative Breast Cancer [Phase 2]
Phase II trial evaluating Ivonescimab with carboplatin and docetaxel in early-stage triple-negative breast cancer is currently recruiting. T…
-
CLINICAL_TRIALS research · 2026-04-01Clinical Trial Update: A First in Human Dose Escalation of Dendritic Cell Vaccine (DCV) [Phase 1]
First-in-human, dose-escalation Phase 1 study of a dendritic cell vaccine (DCV) is underway, with recruitment for leptomeningeal carcinomato…